Literature DB >> 18298331

Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis.

George Sgouros1, Hong Song.   

Abstract

There is increasing recognition that treatment failure in cancer may be associated with the failure to sterilize a small subpopulation of tumor cells that have been characterized as tumor stem cells. Defined as cells that are able to self-renew and also to replenish a phenotypically diverse tumor-cell population, such cells are also considered resistant to chemotherapy. These characteristics are optimal for targeting by using alpha-particle-emitting radionuclides. Because of their high-energy deposition density per track, alpha-particles are capable of targeting single cells or small clusters of cells with minimal normal organ toxicity. The DNA damage induced by alpha-particles is largely irreparable and, therefore, alpha-particle-induced damage is minimally susceptible to resistance mechanisms. In this work, theoretical modeling was performed to examine the potential of alpha-emitter targeting of such small clusters of cancer stem cells. Critical parameters influencing efficacy and toxicity were identified and their relationship elucidated. The results identify specific activity, antigen site density, and number of target cells as critical parameters for effective cell killing and demonstrate substantial efficacy gains by targeting a smaller number of stem cells, as opposed to the entire tumor-cell population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298331      PMCID: PMC2977973          DOI: 10.1089/cbr.2007.0408

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  27 in total

1.  Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei.

Authors:  Y Kvinnsland; T Stokke; E Aurlien
Journal:  Radiat Res       Date:  2001-02       Impact factor: 2.841

2.  Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy.

Authors:  K A Hamacher; R B Den; E I Den; G Sgouros
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

3.  Tumor therapy with targeted atomic nanogenerators.

Authors:  M R McDevitt; D Ma; L T Lai; J Simon; P Borchardt; R K Frank; K Wu; V Pellegrini; M J Curcio; M Miederer; N H Bander; D A Scheinberg
Journal:  Science       Date:  2001-11-16       Impact factor: 47.728

4.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 5.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

6.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Authors:  G Sgouros; A M Ballangrud; J G Jurcic; M R McDevitt; J L Humm; Y E Erdi; B M Mehta; R D Finn; S M Larson; D A Scheinberg
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.

Authors:  Claudia Friesen; Gerhard Glatting; Bernd Koop; Klaus Schwarz; Alfred Morgenstern; Christos Apostolidis; Klaus-Michael Debatin; Sven N Reske
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

8.  Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Authors:  Ase M Ballangrud; Wei-Hong Yang; Stig Palm; Richard Enmon; Paul E Borchardt; Virginia A Pellegrini; Michael R McDevitt; David A Scheinberg; George Sgouros
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

Review 9.  Therapeutic implications of cancer stem cells.

Authors:  Muhammad Al-Hajj; Michael W Becker; Max Wicha; Irving Weissman; Michael F Clarke
Journal:  Curr Opin Genet Dev       Date:  2004-02       Impact factor: 5.578

10.  Targeted alpha particle immunotherapy for myeloid leukemia.

Authors:  Joseph G Jurcic; Steven M Larson; George Sgouros; Michael R McDevitt; Ronald D Finn; Chaitanya R Divgi; Ase M Ballangrud; Klaus A Hamacher; Dangshe Ma; John L Humm; Martin W Brechbiel; Roger Molinet; David A Scheinberg
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

View more
  12 in total

1.  Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.

Authors:  Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

2.  Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.

Authors:  Hong Song; Robert F Hobbs; Ravy Vajravelu; David L Huso; Caroline Esaias; Christos Apostolidis; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

3.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

Authors:  Mengshi Li; Xiuli Zhang; Thomas P Quinn; Dongyoul Lee; Dijie Liu; Falk Kunkel; Brian E Zimmerman; Daniel McAlister; Keith Olewein; Yusuf Menda; Saed Mirzadeh; Roy Copping; Frances L Johnson; Michael K Schultz
Journal:  Appl Radiat Isot       Date:  2017-05-10       Impact factor: 1.513

4.  Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.

Authors:  Alireza Karimian; Nathan T Ji; Hong Song; George Sgouros
Journal:  Cancer Res       Date:  2019-11-26       Impact factor: 12.701

5.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

6.  Radioimmunotherapy of infection with Bi-labeled antibodies.

Authors:  Ekaterina Dadachova
Journal:  Curr Radiopharm       Date:  2008-09-01

7.  MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Authors:  George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

Review 8.  New physical approaches to treat cancer stem cells: a review.

Authors:  H Ghaffari; J Beik; A Talebi; S R Mahdavi; H Abdollahi
Journal:  Clin Transl Oncol       Date:  2018-06-04       Impact factor: 3.405

9.  Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy.

Authors:  Edyta Cędrowska; Marek Pruszynski; Agnieszka Majkowska-Pilip; Sylwia Męczyńska-Wielgosz; Frank Bruchertseifer; Alfred Morgenstern; Aleksander Bilewicz
Journal:  J Nanopart Res       Date:  2018-03-20       Impact factor: 2.253

10.  Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.